Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Cefadroxil

Generic Name: Cefadroxil

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₃O_₅S

CAS Number: 50370-12-2

Unique Ingredient Identifier: Q525PA8JJB

Overview

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Background

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Indication

For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes

Associated Conditions

Bacterial Infections
Infection and inflammatory reaction due to internal prosthetic device, implant, and graft
Skin and Subcutaneous Tissue Bacterial Infections
Streptococcal Pharyngitis
Tonsillitis streptococcal
Urinary Tract Infection

Clinical Trials

Or v IV Antibiotics for Infection

Phase 3

Posted: 2021/01/26

Sponsor:Rothman Institute Or...

ID:NCT04723940

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Phase 4

Posted: 2020/03/05

Sponsor:Mayo Clinic

ID:NCT04297592

Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)

Phase 1

Completed

Posted: 2019/09/11

Sponsor:

Société des Produits...

ID:NCT04085666

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

Phase 1

Completed

Posted: 2019/01/14

Sponsor:University of Colora...

ID:NCT03802552

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Phase 3

Completed

Posted: 2016/06/28

Sponsor:AbbVie

ID:NCT02814916

FDA Approved Products

Cefadroxil

Manufacturer:Aurobindo Pharma Limited

Route:ORAL

Strength:500 mg in 5 mL

Approved: 2024/02/09

NDC:65862-084

Cefadroxil

Manufacturer:Direct_Rx

Route:ORAL

Strength:500 mg in 1 1

Approved: 2023/08/07

NDC:72189-506

Cefadroxil

Manufacturer:NuCare Pharmaceuticals,Inc.

Route:ORAL

Strength:500 mg in 1 1

Approved: 2022/02/07

NDC:68071-5234

Cefadroxil

Manufacturer:Rebel Distributors Corp

Route:ORAL

Strength:500 mg in 1 1

Approved: 2011/03/01

NDC:42254-146

CEFADROXIL

Manufacturer:STAT RX USA LLC

Route:ORAL

Strength:500 mg in 1 1

Approved: 2010/08/11

NDC:16590-043

Singapore Approved Products

SOFIDROX CAPSULE 500 mg

Manufacturer:XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Form:CAPSULE

Strength:500 mg

Online:Yes

Approved: 2001/09/13

Approval:SIN11665P

Related News

FDA Approves FoundationOne CDx as Companion Diagnostic for Tovorafenib in Pediatric Low-Grade Glioma

4 months ago

The FDA has approved FoundationOne CDx as a companion diagnostic for tovorafenib (Ojemda) in pediatric low-grade glioma (pLGG) patients with specific BRAF alterations.

Tempus Launches FDA-Approved xT CDx Test Nationwide for Comprehensive Solid Tumor Profiling

4 months ago

Tempus AI has commercially launched xT CDx, an FDA-approved 648-gene NGS-based diagnostic test for solid tumor profiling, offering comprehensive genomic insights across multiple cancer types.

Precision Medicine and Value-Based Cancer Care: Navigating Implementation Challenges in Academic and Community Settings

5 months ago

Precision medicine adoption in oncology faces distinct challenges in academic and community settings, with issues ranging from workflow variations to bureaucratic constraints in implementing biomarker testing.

Allarity Therapeutics Advances Stenoparib for Ovarian Cancer with Phase 2 Trial Expansion

6 months ago

Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection.

Lyme Disease Treatment Trials: Generalizability Concerns Highlighted

19 years ago

A review questions the broad applicability of chronic Lyme disease treatment trials due to patient selection criteria.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy